May 30 | 2025
NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ).
Read more
May 30 | 2025
KALLELSE TILL ÅRSSTÄMMA I 2CUREX AB (publ).
Read more
May 29 | 2025
PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (PUBL)
Read more
May 29 | 2025
RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT
Read more
May 22 | 2025
2cureX appoints Mangold Fondkommission AB as new Certified Adviser
Read more
May 20 | 2025
2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy
Read more
May 15 | 2025
2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap
Read more
April 14 | 2025
EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)
Read more
February 27 | 2025
2cureX publishes interim report for the second half year of 2024
Read more
January 20 | 2025
2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Read more
January 10 | 2025
Correction: 2CUREX APPOINTS MANGOLD FONDKOMMISSION AB TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Read more
January 10 | 2025
2CUREX APPOINTS MANGOLD CORPORATE FINANCE TO ACT AS A LIQUIDITY PROVIDER FOR THE COMPANY’S SHARE
Read more
December 18 | 2024
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more
December 18 | 2024
KOMMUNIKÉ FRÅN EXTRA BOLAGSSTÄMMA I 2CUREX AB (PUBL)
Read more
December 16 | 2024
2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products
Read more
November 29 | 2024
NOTICE OF EXTRA GENERAL MEETING IN 2CUREX AB
Read more
November 29 | 2024
KALLELSE TILL EXTRA BOLAGSSTÄMMA I 2CUREX AB
Read more
September 24 | 2024
BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)
Read more